You want some Midkine Potential, MJ
Here is some.
PEB gets CMS/and/or KP Approval
CXBladder Monitor which has MK as one of the markers.
800,000 patients in the United States are currently undergoing monitoring for recurrence of Bladder Cancer after having had an operation for tumor removal.
Survey says 57% of patients would prefer to not have a camera inserted after 2 clear cystoscopies and just have a cxbladder type urine test.
If the 57% of 800,000 take this up, which is unlikely, that is 456,000 times an average of 2.5 tests a year that is 1,140,000 tests per annum.
The potential is 1,140,000 times 750US per test which comes to a whopping 855 million US.
The royalties I believe are somewhere around 3% on a CXbladder test.
That is 25,650,000 US and converted to AUD circa 1.35 becomes about 34 million.
This is a handy sum for CDY with not having any further expenditure involved and could most likely be considered ongoing annually.
That is the potential of just one test of the 4 cxbladder suite.
The reality is very likely to be completely different.
CDY Price at posting:
30.5¢ Sentiment: Buy Disclosure: Held
